Osaka University to Pioneer the First Alpha-Ray Therapy Trial for Refractory Prostate Cancer
A research team at Osaka University is launching an investigator-initiated clinical trial for patients with refractory prostate cancer, following the successful development and animal model efficacy confirmation of a new alpha-ray therapeutic agent, [At-211] PSMA-5. This will mark the world’s first in-human clinical trial using [At-211] PSMA-5. Prostate cancer is increasing globally and is the […]









